加藤茂孝先生
|
|
|
- とき はやしもと
- 7 years ago
- Views:
Transcription
1 Shigetaka KATOW WHO TV WHO modern_media@eiken.co.jp RIKEN Center of Research Network for Infectious Diseases (Jimbocho 101 Bldg. 8th fl Kandajimbo-cho, Chiyoda-ku, Tokyo)
2 WHO 6 influenza influence in flow Smith, W. et al.: A virus obtained from influenza patient. Lancet, J. Natl. Inst. Public Health 3,
3 BC Thuchydides 1985 Langmuir 4 2 BC Langmuir, A.D. et al.: The Thuchydides Syndrome. New Eng J Med, 3131, Fields Virology. 5 th ed. D.M. Knipe et al. ed., Lippincott, Williams and Wilkins
4 M
5 R.Pfeiffer Haemophilus influenzae B Hib B B
6 2008 Hib AIDS HIV V B Hib HIV 1933 Smith W 1 A A B 1940 Francis T C 1949 Taylor RM A, B, C A 2 1 HAHemagglutinin 16 1 NANeuraminidase 9 HA NA = HA NA H1N1 H5N1 B B HA 1 NA 1 HA Victoria 2 A H1 H2 C N A B C A 1 RNA 8 1 RNA DNA DNA RNA A
7 A RNA 8 4 RNA A H3N H1N1 H2N2 H3N H1N1 A 20 H1N1 H2N2 H3N21977 A 1 H1N A A AH1N1 A 2 1 2WHO AH3 AH1 BAH3 AH1 B , Beveridge W.I, B.: Influenza : The last great plague. London, Heinenmann
8 H1N H1N A H5N WHO H5N1 H5N H5N1 Cumulative Number of Confirmed Human Cases of Avian Influenza AH5N1Reported to WHO 9 December 2010http:
9 H5N HA H5 H7 1 HA HA H5N H5N1 8 H5N1 4 4 H5 4 International Epizootic OfficeOIE 5, Shinya, K., M. Ebina, S. Yamada, M. Ono, N. Kasai, and Y. Kawaoka. Avian flu : influenza virus receptors in the human airway. Nature :
10 H1N RNA 3 5, i 1933 ii iii A B 2009 iv v 1 80
11 ,000 5,000 1 F Alfred W. Crosby, 2004
12 WHO H1N PCR 14 Teiichiro Shiino et al.: Molecular Evolutionary Analysis of the Influenza AH1N1pdm, May-September, 2009 : Temporal and Spatial Spreading Profile of the Viruses in Japan. 56, e11057, June2010
13 A H1N1A H3N2 B A H1N1 H1N1 3 WHO RNA RNA P. Palese M Enami and P Palese : High-efficiency formation of influenza virus transfectants. J Virol. 5: Neumann, G. et al. Generation of influenza A viruses entirely from cloned cdnas. Proc Natl Acad Sci USA :
14 2009 2,
15 5 ACIP Advisory Committee for Immunization Practices all Japan CDC SARS CDC J.L.Gerberding B CDC
16 CDC Julie Louise Gerberding ACIP 17 GDP R.E. Neustadt, H. V. Fineberg
/‚“1/ŒxŒ{‚×›î’æ’¶
60 1 pp.3-8 2010 1. H1N1 1) 2) 3) 4) ERATO 2009 H1N1 21 H1N1 HA PB2 2009 3 Pandemic H1N1 2009 WHO 6 11 21 2009 11 2010 4 21 H1N1 H1N1 2009 4 15 CDC 108-8639 4-6-1 TEL: 03-5449-5281 FAX: 03-5449-5408 E-mail:
加藤茂孝先生
ooooooo oooooooooooooooooooooooooo 10 30 11 oooooooooooooooooooooooooo Shigetaka KATOW ooooooo 1 1 1 100 1 1 3 2003 SARS SARS 9.11 2 2 30 2003 SARS 2009 200 SARS 1 2001 0101-0051 - RIKEN Center of Research
›Áfi¡ŒÎ“F’æ’¶
Shigetaka KATOW 2002 12 13 2 CDC Centers for Disease Control and Prevention CDC TV Dr. Julie L. Gerberding CDC 1 2001 9 11 2001 7 3 2 TV 60 2009 2 1 3 50 30 1976 1 5 BC1157 1 DNA DNA RNA 0100-0006 - -
11月/庵原俊昭
Shigetaka KATOW 1947 2 1595 1592 1592 1594 250 1347 1353 3 1 Yersinia pestis 1 Yersinia pseudotuberculosis 1500 2 2 1 1 2 http: ja.wikipedia.org wiki E3 83 9A E3 82 B9 E3 83 88 E8 8F 8C Achtman, M. et
表1.eps
Vol.1 C ontents 1 2 cell-free EMBO J Proc. Natl. Acad. Sci. USA NatureEMBO J 3 RNA NatureEMBO J Nature EMBO J 4 5 HCV HCV HCV HCV RNA HCV in situ 6 7 8 Nat Struct Mol Biol J Biol Chem Nat Commun J Virol
加藤茂孝先生
ooooo ooooooooooooooooooooooooo 10 1 7 ooooooooooooooooooooooooo Shigetaka KATOW ooooo 1. 2011 3 11 2 995 2. 10 0101-0051 - RIKEN Center of Research Network for Infectious Diseases Jimbocho 101 Bldg. 8th
untitled
18 12 10 40 H5N1 2005 11 WHO 2005 12 2006 6 (H5N1) 10 25 1,700 ( 1,300 2,500 ) 200 53 64 17 30% 3,785,000 291,200 3 14,100 4 30% 57,600 4,430 3 1,150 320 210 4 2% 0.56% () ) 1 10 2 3A (2B) 3B 4A5A 6A 4B
11月/庵原俊昭
Shigetaka KATOW 2001 10 Kandahar BC 330 Alexander 1 al-iskandar Iskandar 74 Alexandria Arachosiorum 100km 2 BC323 6 10 2 6 18 28 1 1 BC333 Bucephalus.. http:upload.wikimedia.org wikipedia commons a ac
11月/庵原俊昭
Shigetaka KATOW 1 1 2 2 3 1 1 1960 5 10 1 8 1 1 1 6 Irtyersenu BC600 2009 1 9,000 2 2008 2 2009 1 AD1 50 DNA 0100-0006 - - RIKEN Center of Research Network for Infectious Diseases (Yurakucho-Denki Bldg.
provider_020524_2.PDF
1 1 1 2 2 3 (1) 3 (2) 4 (3) 6 7 7 (1) 8 (2) 21 26 27 27 27 28 31 32 32 36 1 1 2 2 (1) 3 3 4 45 (2) 6 7 5 (3) 6 7 8 (1) ii iii iv 8 * 9 10 11 9 12 10 13 14 15 11 16 17 12 13 18 19 20 (2) 14 21 22 23 24
労 働 Health Care Quality Indicators Project - 6 data collection update report (OECD Health Working Paper No. 29) 5-Oct-7 HPV-18 ( 99 HPV 8 HPV 9 B B C
2 3-29 1 1 労 働 Health Care Quality Indicators Project - 6 data collection update report (OECD Health Working Paper No. 29) 5-Oct-7 HPV-18 ( 99 HPV 8 HPV 9 B B C 8 5 >5 1 1 / 1.1.6 Baseline reference (
44 4 I (1) ( ) (10 15 ) ( 17 ) ( 3 1 ) (2)
(1) I 44 II 45 III 47 IV 52 44 4 I (1) ( ) 1945 8 9 (10 15 ) ( 17 ) ( 3 1 ) (2) 45 II 1 (3) 511 ( 451 1 ) ( ) 365 1 2 512 1 2 365 1 2 363 2 ( ) 3 ( ) ( 451 2 ( 314 1 ) ( 339 1 4 ) 337 2 3 ) 363 (4) 46
i ii i iii iv 1 3 3 10 14 17 17 18 22 23 28 29 31 36 37 39 40 43 48 59 70 75 75 77 90 95 102 107 109 110 118 125 128 130 132 134 48 43 43 51 52 61 61 64 62 124 70 58 3 10 17 29 78 82 85 102 95 109 iii
フィナレビ106号.indb
2009 3 30 2009 4 14 CDC 2009 4 25 WHO 2009 4 26 2009 4 28 2009 4 28 2009 4 30 2009 5 1 2009 5 8 6 2009 5 9 2009 5 23 2009 6 3 2009 6 9 2500 2009 6 12 WHO 6 2009 6 28 2009 8 9 1 1 2009 8 15 2009 8 19 2010
SURF 200000300104 Sendai Urban Research Forum 1 1 1 4 5 5 5 5 6 8 8 13 17 18 20 20 23 29 35 35 35 35 36 36 37 37 39 40 44 44 45 45 49 51 52 54 60 52 63 69 69 70 71 72 73 70 70 70 71 71 72 74 78 86 102
/fiÁ1-1/‹Éfi¡ıæ„[’æ’¶
59 1 pp.53-58 2009 1. H5N1 3 H5N1 2007 1 2 2008 4 5 2003 H5N1 2005 50 1 429 262 2009 5 22 2 680-8553 4 101 TEL/FAX : 0857-31-5437 E-mail: toshiito@muses.tottori-u.ac.jp 3 H5N1 1 A A A 54 59 1 4 A A 5 1997
i
14 i ii iii iv v vi 14 13 86 13 12 28 14 16 14 15 31 (1) 13 12 28 20 (2) (3) 2 (4) (5) 14 14 50 48 3 11 11 22 14 15 10 14 20 21 20 (1) 14 (2) 14 4 (3) (4) (5) 12 12 (6) 14 15 5 6 7 8 9 10 7
86 7 I ( 13 ) II ( )
10 I 86 II 86 III 89 IV 92 V 2001 93 VI 95 86 7 I 2001 6 12 10 2001 ( 13 ) 10 66 2000 2001 4 100 1 3000 II 1988 1990 1991 ( ) 500 1994 2 87 1 1994 2 1000 1000 1000 2 1994 12 21 1000 700 5 800 ( 97 ) 1000
A4 3 mortality morbidity 63
2006 7 20 84 21 1 1 7 20 21 A4 3 mortality morbidity 63 1 20 1947 1 28 18 28 38 SARS major issue minor issues 243 Nature Science 6 E HEV genome RNA HEV RNA 1910 Indian mongoose HEV HEV 2 HEV 1 4 0.35
1937 West Nile HA 1957 A/H5 H7 A H1 15 N1 9 A(H1N1) A(H2N2) A(H3N2)
DNA RNA capsid 20 56 30 60 70 30 100 98 98 15 20 2w/v 0.05 0.5w/v 500 5,000ppm 76.9 81.4v/v 70v/v 2.5w/v 0.55w/v 0.3w/v ) ( ) 1937 West Nile 14 39 HA 1957 A/H5 H7 A H1 15 N1 9 A(H1N1) A(H2N2) A(H3N2) 2003
第１部 一般的コメント
(( 2000 11 24 2003 12 31 3122 94 2332 508 26 a () () i ii iii iv (i) (ii) (i) (ii) (iii) (iv) (a) (b)(c)(d) a) / (i) (ii) (iii) (iv) 1996 7 1996 12
表1票4.qx4
iii iv v 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 22 23 10 11 24 25 26 27 10 56 28 11 29 30 12 13 14 15 16 17 18 19 2010 2111 22 23 2412 2513 14 31 17 32 18 33 19 34 20 35 21 36 24 37 25 38 2614
4) H. Takayama et al.: J. Med. Chem., 45, 1949 (2002). 5) H. Takayama et al.: J. Am. Chem. Soc., 112, 8635 (2000). 6) H. Takayama et al.: Tetrahedron Lett., 42, 2995 (2001). 9) M. Kitajima et al: Chem.
第１章 国民年金における無年金
1 2 3 4 ILO ILO 5 i ii 6 7 8 9 10 ( ) 3 2 ( ) 3 2 2 2 11 20 60 12 1 2 3 4 5 6 7 8 9 10 11 12 13 13 14 15 16 17 14 15 8 16 2003 1 17 18 iii 19 iv 20 21 22 23 24 25 ,,, 26 27 28 29 30 (1) (2) (3) 31 1 20
Various function and toxicity of iron Key words 1) Hentze, M. W. et al: Cell, 117, 285-297 (2004) 2) Ganz, T.: Blood, 102, 783-788 (2003) 3) Nemeth, E. et al.: Science, 306, 2090-2093 (2004) 4) Hentze,
029 Meg D. Newman Meg D. Newman, MD.: New Developments in HIV Care for Women. From the AIDS Education, the UCSF Positive Health Program, San Francisco General Hospital Medical Center, 995 Potrero Ave c/o
untitled
c OR 21 OR 1. 21 21 IoT OR OR OR 260 8672 1 8 1 OR 2. 2.1 public health [1] communicable (infectious) diseases vehicle burden HIV/AIDS (SARS) 258 60 Copyright c by ORSJ. Unauthorized reproduction of this
437“ƒ
et al., et al., et al., et al., et al., et al., 2 et al., et al., et al., Lancet Pharmacol Res. et al. Jpn J Cancer Res. et al. Jpn J Cancer Res. et al. Tohoku J Exp Med. et al. Jpn Circ J. et al. Cancer
20 15 14.6 15.3 14.9 15.7 16.0 15.7 13.4 14.5 13.7 14.2 10 10 13 16 19 22 1 70,000 60,000 50,000 40,000 30,000 20,000 10,000 0 2,500 59,862 56,384 2,000 42,662 44,211 40,639 37,323 1,500 33,408 34,472
I? 3 1 3 1.1?................................. 3 1.2?............................... 3 1.3!................................... 3 2 4 2.1........................................ 4 2.2.......................................
- 2 -
- 2 - - 3 - (1) (2) (3) (1) - 4 - ~ - 5 - (2) - 6 - (1) (1) - 7 - - 8 - (i) (ii) (iii) (ii) (iii) (ii) 10 - 9 - (3) - 10 - (3) - 11 - - 12 - (1) - 13 - - 14 - (2) - 15 - - 16 - (3) - 17 - - 18 - (4) -
2 1980 8 4 4 4 4 4 3 4 2 4 4 2 4 6 0 0 6 4 2 4 1 2 2 1 4 4 4 2 3 3 3 4 3 4 4 4 4 2 5 5 2 4 4 4 0 3 3 0 9 10 10 9 1 1
1 1979 6 24 3 4 4 4 4 3 4 4 2 3 4 4 6 0 0 6 2 4 4 4 3 0 0 3 3 3 4 3 2 4 3? 4 3 4 3 4 4 4 4 3 3 4 4 4 4 2 1 1 2 15 4 4 15 0 1 2 1980 8 4 4 4 4 4 3 4 2 4 4 2 4 6 0 0 6 4 2 4 1 2 2 1 4 4 4 2 3 3 3 4 3 4 4
1 (1) (2)
1 2 (1) (2) (3) 3-78 - 1 (1) (2) - 79 - i) ii) iii) (3) (4) (5) (6) - 80 - (7) (8) (9) (10) 2 (1) (2) (3) (4) i) - 81 - ii) (a) (b) 3 (1) (2) - 82 - - 83 - - 84 - - 85 - - 86 - (1) (2) (3) (4) (5) (6)
1 1 1 2 2 3 3 4 5 6 6 7 8 8 8 9 10 10 14 16 17 17 18 18 18 23 27 27 27 28 29 29 30 30 31 32 32 33 34 34 35 36 37 38 38
2007 2006 11 29 1 1 1 2 2 3 3 4 5 6 6 7 8 8 8 9 10 10 14 16 17 17 18 18 18 23 27 27 27 28 29 29 30 30 31 32 32 33 34 34 35 36 37 38 38 40 40 40 11 41 41 42 42 43 43 44 45 46 46 47 47 49 50 51 51 52 53
座談会/2009
6 2008 10 3 9 2008 2 9 Asian-African Research Network 4 A preliminary experiment of Japan over these four years05 08 1900 2000 50 3 50 3 1969 Surgeon General William T. Stewart 2003 SARS SARS 2003 2 M
yakugaku-kot.ppt
2009 Masaaki Kotera kot@kuicr.kyoto-u.ac.jp 2 I II / A () B1 () B2 B12 C () D A D () () () () DNA 5- http://www.genome.jp/kegg/pathway.html KEGG PATHWAY Database Xenobiotics biodegradation http://www.genome.jp/kegg/pathway.html
Short Review Hidenori Takagi, Fumio Takaiwa, E-mail : takaiwa@nias.affrc.go.jp 13) Hirahara, K. et al. : J. Allergy Clin. Immunol., 102, 961-967 (1998) 14) Takagi, H. et al.: Proc. Natl. Acad. Sci.
在外教育施設派遣教員安全対策資料 在外教育施設派遣教員安全対策資料
1. 1. 1.1.1. 1.1.2. 1.1.3. 1.1.4. 1.1.5. 1. 2. 1. 3. 1. 4. 1-1 1-2 1-3 2. 1. 2. 2. 2. 3. 2. 4. 2.4.1. 2.4.2. 2-1 2. 5. 2. 6. 2.6.1. 2.6.2. 2.6.3. 2.6.4. 2.6.5. 2. 7. 2.7.1. 2.7.2. 2.7.3. 2.7.4. 2. 8. 2.
State Committee of Russian Federation on Statistics 1 2 12 State Committee of Russian Federation on Statistics 53
I State Committee of Russian Federation on Statistics 52 State Committee of Russian Federation on Statistics 1 2 12 State Committee of Russian Federation on Statistics 53 State Committee of Russian Federation
untitled
2005 10 13 Dr. RGA 19602000 10 Australian Institute of of Health and and Welfare 2004 ABS Cat. Cat. No. No. 3201.0; AIHW National Population Database 1875 2 211997 8 122164 http://www.wowzone.com/calment.htm
「産業上利用することができる発明」の審査の運用指針（案）
1 1.... 2 1.1... 2 2.... 4 2.1... 4 3.... 6 4.... 6 1 1 29 1 29 1 1 1. 2 1 1.1 (1) (2) (3) 1 (4) 2 4 1 2 2 3 4 31 12 5 7 2.2 (5) ( a ) ( b ) 1 3 2 ( c ) (6) 2. 2.1 2.1 (1) 4 ( i ) ( ii ) ( iii ) ( iv)
Novel chemical mediators in the resolution of inflammation Charles N. Serhan Key words E-mail : marita@nih.go.jp Charles N. Serhan Brigham & Women's Hospital/Harvard Medical School 1) Serhan, C. N.,
Fig. 1 Trends of TB incidence rates for all forms and smear-positive pulmonary TB in Kawasaki City and Japan. Incidence=newly notified cases of all fo
Kekkaku Vol. 79, No. 1: 17-24, 2004 17 (Received 21 Aug. 2003/Accepted 18 Nov. 2003) Fig. 1 Trends of TB incidence rates for all forms and smear-positive pulmonary TB in Kawasaki City and Japan. Incidence=newly
東北病理標本検討会（東北支所－2007）における事例
ull. Natl. Inst. nim. Health No. 115. 19 30 ( January 2009) ull. Natl. Inst. nim. Health No. 115. 19 30 ( January 2009) ull. Natl. Inst. nim. Health No. 115. 19 30 ( January 2009) ull. Natl. Inst. nim.
19-4.3.1.3-4.3.1.3 541
4.3 4.3.1 3.1.2 GIS -4.3.1.1 1856 3 3.1.2-4.3.1.2 2003-4.3.1.1-4.3.1.2 540 19-4.3.1.3-4.3.1.3 541 4.3.2 3.1.2(2) -4.3.2.1 3.1.2(2) 2-4.3.2.1-4.3.2.2-4.3.2.5-4.3.2.1 542 (1) - 4.3.2.2 : 543 (2) - 4.3.2.3
Database Center for Life Science Online Service 35) [Laboratory of Hepatitis Viruses II, Department of Enteroviruses, National Institute of Health, Ka
35) [Laboratory of Hepatitis Viruses II, Department of Enteroviruses, National Institute of Health, Kamiosaki, Shinagawa-ku, Tokyo 141, Japan] Hepatitis C Virus 1) Choo, Q.-L., Kuo, G., Weiner,
i ii iii iv v vi vii ( ー ー ) ( ) ( ) ( ) ( ) ー ( ) ( ) ー ー ( ) ( ) ( ) ( ) ( ) 13 202 24122783 3622316 (1) (2) (3) (4) 2483 (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) 11 11 2483 13
/ /
/ ( 2009 9 17 / / Transboundary Animal Diseases Emerging (Re-emerging) Animal Diseases OIE) 100 OIE / / (SARS) HPAI) H1N1 2009(A/H1N1) BSE (Monkey pox) (FMD) (CSF) (PRRS) (Rinderpest) (Rift Valley Fever)
表1_表4
HN- 95 HN- 93 HN- 90 HN- 87 HN- 85 HN- 82 HN- 80 HN- 77 HN- 75 HN- 72 HN- 70 HN- 67 HN- 65 HN- 60 HN- 55 HN- 50 HN- 45 HN- 40 HN- 35 HN- 30 HN- 25 HN- 20 HN- 15 HN- 10 H02-80H H02-80L H02-70T H02-60H H05-60F
能書単頁9[1].5(2)
![能書単頁9[1].5(2)](/thumbs/87/96620151.jpg "能書単頁9[1].5(2)")
ips CytoTune -ips ver.1.0 1 I CytoTune ips 3 II 3 3 4 5 III CytoTune ips ips 6 6 6 6 7 1) 2) ips 8 ips 8 SeV 9 SeV 10 IV Q&A 11 V 12 12 VI...13 13...13 2 I CytoTune ips CytoTune ips 4 OCT3/4SOX2 KLF4c
会報35号表紙.pdf
35 No. (2017 1 ) RNA 2017 2017 TV 365 365 chunky 26 RNA 2017 Congratulations26 30-1 - RNA 2017-2 - - 3 - - 4 - - 5 - - 6 - 2016 8 31 9 2 RNA 2016 1 RNA RNA RNA RNA RNA 1-7 - RNA RNA 3 3 7 31 RNA ncrna
untitled
HBV HBV (1964) HDV (1977) HCV (1988) 2009 Yotsuyanagi H et al. J Med Virol 2005 Yotsuyanagi H et al. J Hepatol 2002 Universal vaccination (UV) 45 HB 2009 1/3 Progress Toward the Elimination
第1回土地改良研修会
2006.5.11 26 51 62 8 56 62 6 56 8 3 1-1 - P 1 3 25 1 2 5 2000 3 24 1 2 3 4 1 4 2 2 A4 5 6 2 1961 5 5-2 - 1 1 5 2009 2007 5 3 10 27 8 8 3 3 3 5 10-3 - P 2 3 3 2003 8 29 2003 8 29 3 3 3 2 3 1 1 1 1-4 - 2000
1) Garner J. S.: The Hospital Infection Control Practices Advisory Committee, CDC, Guidelines for Isolation Precautions in Hospitals, 1996. http://wonder.cdc.gov/wonder/prevguid/ p0000419/p0000419.asp.
178 5 I 1 ( ) ( ) 10 3 13 3 1 8891 8 3023 6317 ( 10 1914 7152 ) 16 5 1 ( ) 6 13 3 13 3 8575 3896 8 1715 779 6 (1) 2 7 4 ( 2 ) 13 11 26 12 21 14 11 21
I 178 II 180 III ( ) 181 IV 183 V 185 VI 186 178 5 I 1 ( ) ( ) 10 3 13 3 1 8891 8 3023 6317 ( 10 1914 7152 ) 16 5 1 ( ) 6 13 3 13 3 8575 3896 8 1715 779 6 (1) 2 7 4 ( 2 ) 13 11 26 12 21 14 11 21 4 10 (
1-1 - 2 3-2 - - 3 - i - 4 - ii - 5 - c - 6 - 4 1-7 - 2 1-8 - 2-9 - - 10 - - 11 - - 12 - - 13 - - 14 - - 15 - - 16 - - 17 - 3-18 - - 19 - - 20 - - 21 - - 22 - - 23 - iii i - 24 - - 25 - - 26 - 4-27 - 5
1 1.1 ワクチンの定義 Variolae vaccinae 1798 1 1. A B b Hib 2 1 4 2012 1. 2012 5 2. 1 1 13 bb 3 B b 3. 6 2012 1 3 23 1.2 4 3 A B DTaP Tdap bhib 2 HPV H1N1 3. 2 AS04 A MF59 2 2. 1... http://www.fda.gov/biologicsbloodvaccines/safetyavailability/vaccinesafety/ucm096228#t2
untitled
1 1 11 12 2 21 22 23 3 31 32 33 34 4 41 42 5 2 1 2 2 3 3 1 4 5 3 111 43 142 32.8km 27.3km 600.972 15 10 1 7 112 11 4 1m 23 11 6.8 34.125.5 1,418 1,192mm 2 3 7 9 200 00 113 4 11 12 16 26,252 25,452 12,528
広域防災拠点検討会報告書030723表紙_0829_.PDF
15 3 i 15 3 ii iii iv ( ) ( ) ( ) ... i...iii... 1.... 1.... 1..... 1..... 2.... 3... 5.... 5..... 5..... 5.... 6..... 6..... 6.... 7..... 7..... 8... 12... 13.... 13..... 13..... 16..... 16.... 17....
橡Taro11-報告書０.PDF
Research Center RC 2001 5-1- RC RC NHK -2- -3- 00/12/16 RC 01/01/07 RC 01/01/21 1 13 01/02/11 2 9 01/02/10 01/02/14 01/02/19 01/02/25 3 7 01/03/10 4 8 01/03/23 5 8 01/04/29 2001/01/07-4- -5- RC 1990 RC
(Travel Medicine) (Emerging Re-emerging Diseases) ) ) ) ) ) ) ) 10 ) 12 ) ) 12 ) 13 ) 14 ) 15 ) 17 ) 18 ) 20 ) 22 24
1999.No2(22) (Travel Medicine) (Emerging Re-emerging Diseases) ) ) ) ) ) ) ) 10 ) 12 ) ) 12 ) 13 ) 14 ) 15 ) 17 ) 18 ) 20 ) 22 24 Travel Medicine Travel Clinic i) ii) iii) ) 200 Emerging Re-emerging Diseases
( ) ー ( () ) 250 200 150 100 50 0 51 20 54 59 33 35 91 92 93 98 99 94 6 7 7 8 9 11 18 17 18 20 22 23 10 9 8 9 9 9 62 40 66 74 41 47 21 22 23 24 25 26 10 8 6 4 2 0 m3/s 7 41.3 5 5 18.4
Database Center for Life Science Online Service Miho Shimizu, [Faculty of Pharmaceutical Sciences, Hokkaido University, Kita-12, Nishi-6, Kita-ku, Sap
Miho Shimizu, [Faculty of Pharmaceutical Sciences, Hokkaido University, Kita-12, Nishi-6, Kita-ku, Sapporo 060, Japan] Molecular Basis of Triplet Repeat Diseases : Genetic Instabillity and Unusual DNA
et al No To Shinkei Clin Neurol Neurology et al J Neurosurg et al Arch Neurol et al Angiology
37 Recommendations for the Management of Moyamoya Disease A Statement from Research Committee on Spontaneous Occlusion of the Circle of Willis (Moyamoya Disease) Research on intractable diseases of the
2007050781......_.L.O...z.W
a s d f g a s d f g h j k l 0 in vitro in vivo in vitro in vivo in vivo in vivo in vitro Metabolism Metabolism Endocr Endocr Endocrinol Ann NYA cad Sci J clin Endocr Metab
59...ec6
No.59 2012 1 SIV SIV SIV HA NA PB1 PB2 PA NP M NS (H3N2) SIV (H1N1) SIV (H1N1) (H3N2) (H1N1) H1N2 H3N2 H1N2 H1N1 SIV (H1N1)2009 2 Proc Jpn Pig Vet Soc No.59 2012 No.59 2012 3 4 Proc Jpn Pig Vet Soc No.59
History I COE
2008 108-8641 5-9-1 TEL 03-5791-6334FAX 03-5791-6335 e-mailgakufu@lisci.kitasato-u.ac.jp 228-8555 1-15-1 TEL 042-778-9760FAX 042-778-9761 e-mailnyushi@kitasato-u.ac.jp URL http://www.kitasato-u.ac.jp/lisci/index.html
i
i ii iii iv v vi vii viii ix x xi ( ) 854.3 700.9 10 200 3,126.9 162.3 100.6 18.3 26.5 5.6/s ( ) ( ) 1949 8 12 () () ア イ ウ ) ) () () () () BC () () (
Staff and Research Fields 124
123 Staff and Research Fields 124 125 Staff and Research Fields 126 127 Staff and Research Fields 128 129 Staff and Research Fields 130 131 Staff and Research Fields 132 133 Staff and Research Fields 134
2014Vol.63No.4p.342349 New impediment factor to health: biological contamination U YANAGI School of Architecture, Kogakuin University Abstract More than 40 years have passed since the Act on Maintenance
小児感染免疫第23巻第1号
Vol. 23No. 163 42 HPV HPV 1113 HPV 42 HPV HPV HPV 1 1 510 1020 HPV 1020 510 HIV 0.1 0.005 HIV 2030 HIV 0.2 510 HPV 1020 15 HIV 2030 HIV HIV 0.2 0.1 Takeyuki Sato 2608677 181 64 2011 2 1 1518 6,000 513
香港
FTA CEPA 1970 1980 1980 51 1999 1998 24 2000 2007 2006 11 52 1999 FTA FTA FTA 2001 11 WTO WTO FTA FTA 53 FTA CEPA FTA WTO FTA CEPA 2000 FTA FTA 2000 17 FTA 2000 11 WTO 2000 FTA WTO FTA FTA FTA FTA 2001
Key words : influenza, nested-pcr, serotype
Key words : influenza, nested-pcr, serotype Table 1 Sequence of PCR primers used to detect HA gene of influenza virus 524 清水 Fig. 1 Detection of PCR product 英明 他 (lstpcr) Table 2 Results method Fig. 2
untitled
i ii iii iv v 43 43 vi 43 vii T+1 T+2 1 viii 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 a) ( ) b) ( ) 51
AccessflÌfl—−ÇŠš1
ACCESS ACCESS i ii ACCESS iii iv ACCESS v vi ACCESS CONTENTS ACCESS CONTENTS ACCESS 1 ACCESS 1 2 ACCESS 3 1 4 ACCESS 5 1 6 ACCESS 7 1 8 9 ACCESS 10 1 ACCESS 11 1 12 ACCESS 13 1 14 ACCESS 15 1 v 16 ACCESS
untitled
Fig.1 t O O N,N p n J J J J J t J J J J J J J J J J J t t J J J J J J J J J p Fig.2 p t Fig.3 Fig.4 synanti p Table1 Table2t Table2 synanti antisyn synanti synanti Fig.5 syn anti anti Fig.6 Table3 Table4
14UNAIDS HIV 39% i 9 ii9iii UNAIDS x.9x.9x1= ?? UNAIDS % 77%8% 44.7x.77x.8x1=
DeCEMBER, 17 No.34 HIV 169-73 1-1-1-13TEL 3-5937-4413:3 19:3 FAX 3-5937-443E-mail info@janpplus.jp http://janpplus.jp/!9-9-9!... 1-3 POSITIVE HIV/AIDS UNAIDS!... 4-5 JaNP+HIV Cafe Bar an opportunity...
2
1 2 3 4 5 6 7 8 9 10 I II III 11 IV 12 V 13 VI VII 14 VIII. 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 _ 33 _ 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 VII 51 52 53 54 55 56 57 58 59
星医会00表紙.pdf
H A,, , ,,, Facebook PSP PSP in situ hybridization New York Bronx Veterans Administration Hospital, Alcohol Research and Treatment Center demanding education e-ducare S. M. McCann Proc. Natl. Acad.
矛盾深まる中国の農地制度――経済成長に取り残された農民――（農林金融2010年08月号）
GDP11 GDP 60 1978 9695 9,497ha96 3,000ha36.9 96 667m 2 1,000m 2 95667m 2 06 95 78 95189,939ha 9,497ha442ha 24.5ha960813 3,000ha 2,172ha832ha64 ha9608 96 32.613 22.613.59.6 9.2 10 0203 86 99 2433 80 34